DE69432124D1 - Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes - Google Patents

Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes

Info

Publication number
DE69432124D1
DE69432124D1 DE69432124T DE69432124T DE69432124D1 DE 69432124 D1 DE69432124 D1 DE 69432124D1 DE 69432124 T DE69432124 T DE 69432124T DE 69432124 T DE69432124 T DE 69432124T DE 69432124 D1 DE69432124 D1 DE 69432124D1
Authority
DE
Germany
Prior art keywords
pct
medicine
production
inositol triphosphate
triphosphate ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69432124T
Other languages
English (en)
Inventor
Matti Siren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioneris Lidingoe Se AB
Original Assignee
Perstorp AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perstorp AB filed Critical Perstorp AB
Application granted granted Critical
Publication of DE69432124D1 publication Critical patent/DE69432124D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69432124T 1993-11-22 1994-11-18 Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes Expired - Lifetime DE69432124D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9303853A SE502989C2 (sv) 1993-11-22 1993-11-22 Användning av en inositoltrisfosfatester för beredning av läkemedel
PCT/SE1994/001091 WO1995014475A1 (en) 1993-11-22 1994-11-18 The use of an ester of inositoltrisphosphate for the preparing of medicaments

Publications (1)

Publication Number Publication Date
DE69432124D1 true DE69432124D1 (de) 2003-03-20

Family

ID=20391828

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432124T Expired - Lifetime DE69432124D1 (de) 1993-11-22 1994-11-18 Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes

Country Status (8)

Country Link
US (1) US5846957A (de)
EP (1) EP0730459B1 (de)
JP (1) JP3769011B2 (de)
AT (1) ATE232387T1 (de)
AU (1) AU1081695A (de)
DE (1) DE69432124D1 (de)
SE (1) SE502989C2 (de)
WO (1) WO1995014475A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602463D0 (sv) * 1996-06-24 1996-06-24 Perstorp Ab The use of growth factor modulating compounds
WO1998044935A2 (en) * 1997-04-09 1998-10-15 Viron Corporation Antiviral composition containing oxidized inositol, sodium sulfite, pyrocatechol and copper sulfate
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
ES2383673T3 (es) * 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7084115B2 (en) 2002-04-29 2006-08-01 Oxyplus, Inc. Inositol pyrophosphates, and methods of use thereof
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
WO2006102060A1 (en) * 2005-03-18 2006-09-28 Oxyplus, Inc. Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin
AU2008246061A1 (en) * 2007-05-01 2008-11-06 Normoxys, Inc. Erythropoietin complementation or replacement

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023248A (en) * 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
US5015634A (en) * 1986-04-16 1991-05-14 Perstorp Ab Method of treating tissue damage with inositol triphosphate
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US5407924A (en) * 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
US5545632A (en) * 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
US5128332A (en) * 1984-10-23 1992-07-07 Perstorp Ab Method of treating cardiovascular diseases using inositoltrisphosphate
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
US5057507A (en) * 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
US5135923A (en) * 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
SE8605063D0 (sv) * 1986-11-26 1986-11-26 Matti Siren Derivatives of cyclohexane
US4997761A (en) * 1987-10-06 1991-03-05 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
US5082833A (en) * 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity

Also Published As

Publication number Publication date
JP3769011B2 (ja) 2006-04-19
ATE232387T1 (de) 2003-02-15
WO1995014475A1 (en) 1995-06-01
AU1081695A (en) 1995-06-13
JPH09505579A (ja) 1997-06-03
SE9303853L (sv) 1995-05-23
SE9303853D0 (sv) 1993-11-22
SE502989C2 (sv) 1996-03-04
EP0730459A1 (de) 1996-09-11
US5846957A (en) 1998-12-08
EP0730459B1 (de) 2003-02-12

Similar Documents

Publication Publication Date Title
ATE94387T1 (de) Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
UA19782A (uk) Спосіб одержаhhя біциклічhих складhих ефірів або їх фармацевтичhо прийhятhих солей
DE69432140T2 (de) Verfahren zur Herstellung von 9-Desoxotaxanen
DE69432124D1 (de) Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes
DE69506686T2 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE68902526D1 (de) Verwendung von inositoltriphosphat zur herstellung eines arzneimittels gegen stoerungen bei transplantationen.
ATE236139T1 (de) Verfahren zur herstellung von 2-chlor-5- chlomethyl-thiazol-derivaten
DE69420832D1 (de) Die Verwendung von Carbostyrilderivaten zur Herstellung eines Arzneimittels zur Hemmung der Produktion von Interleukin-8
DE69635057D1 (de) Verfahren zur herstellung von campothecinderivate
ATE247474T1 (de) Verwendung von inosittriphosphat zur herstellung von arzneimitteln
DE69329687T2 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
HU9503099D0 (en) New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components
ATE173259T1 (de) Verfahren zur herstellung von indolizinderivaten
DE69109293T2 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ES2122005T3 (es) Medicamento que contiene (-)-metrifonato.
DE69514512D1 (de) Verfahren zur herstellung von benzopyranderivaten
ES2147601T3 (es) Procedimiento para la preparacion de 3-amino-2-cloro-4-alquil-piridinas o 3-amino-2-cloro-4-cicloalquil-piridinas.
AU7695596A (en) Use of 1-hydroxy-2-pyridones for treating mucosa diseases which are difficult to treat
SE9303289L (sv) Användning av inositoltrisfosfat för beredning av läkemedel
PL309339A1 (en) Novel triazoquinazolines, methods of obtaining them and their application
SE9303855D0 (sv) The use of ester of inositoltrisphosphate for the preparing of an analgetic medicamnet
DE69620244T2 (de) Verfahren zur herstellung von prostaglandin e1

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BIONERIS AB, LIDINGOE, SE

8332 No legal effect for de